Literature DB >> 9145883

Interpretive criteria for testing susceptibility of staphylococci to mupirocin.

J E Finlay1, L A Miller, J A Poupard.   

Abstract

To determine appropriate mupirocin susceptibility testing interpretive criteria, 177 staphylococci were tested by agar dilution, disk diffusion, and E test. E test was found to be a reliable method for determining susceptibility of staphylococci to mupirocin. The agar dilution and disk diffusion results were plotted on a scattergram, and error rates were calculated. No errors were found with susceptibility breakpoints of > or = 4 microg/ml (MIC) and > or = 14 mm (zone diameter).

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9145883      PMCID： PMC163864     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  Interpretive criteria for disk diffusion susceptibility testing of mupirocin, a topical antibiotic.

Authors:  P C Fuchs; R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

2.  Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.

Authors:  C M Metzler; R M DeHaan
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

3.  Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. The Mupirocin Collaborative Study Group.

Authors:  B N Doebbeling; D L Breneman; H C Neu; R Aly; B G Yangco; H P Holley; R J Marsh; M A Pfaller; J E McGowan; B E Scully
Journal:  Clin Infect Dis       Date:  1993-09       Impact factor: 9.079

4.  Ramoplanin susceptibility testing criteria.

Authors:  A L Barry; M A Pfaller; P C Fuchs
Journal:  J Clin Microbiol       Date:  1993-07       Impact factor: 5.948

Review 5.  The efficacy of intranasal mupirocin in the prevention of staphylococcal infections: a review of recent experience.

Authors:  I R Hudson
Journal:  J Hosp Infect       Date:  1994-06       Impact factor: 3.926

6.  Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use.

Authors:  R Sutherland; R J Boon; K E Griffin; P J Masters; B Slocombe; A R White
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

Review 7.  Update on mupirocin resistance.

Authors:  J A Poupard
Journal:  J Chemother       Date:  1995-07       Impact factor: 1.714
  7 in total
  30 in total

1.  Quality control guidelines for MIC susceptibility testing of omiganan pentahydrochloride (MBI 226), a novel antimicrobial peptide.

Authors:  Tamara R Anderegg; Thomas R Fritsche; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

2.  High-level mupirocin resistance within methicillin-resistant Staphylococcus aureus pandemic lineages.

Authors:  Eduardo Pérez-Roth; Celeste López-Aguilar; Julia Alcoba-Florez; Sebastián Méndez-Alvarez
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Mupirocin - Are we in danger of losing it?

Authors:  John M Conly; B Lynn Johnston
Journal:  Can J Infect Dis       Date:  2002-05

4.  Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial.

Authors:  Sander Koning; Lisette W A van Suijlekom-Smit; Jan L Nouwen; Cees M Verduin; Roos M D Bernsen; Arnold P Oranje; Siep Thomas; Johannes C van der Wouden
Journal:  BMJ       Date:  2002-01-26

Review 5.  Antimicrobial Resistance to Agents Used for Staphylococcus aureus Decolonization: Is There a Reason for Concern?

Authors:  Gregory R Madden; Costi D Sifri
Journal:  Curr Infect Dis Rep       Date:  2018-06-07       Impact factor: 3.725

6.  Mupirocin prophylaxis against methicillin-susceptible, methicillin-resistant, or vancomycin-intermediate Staphylococcus epidermidis vascular-graft infection.

Authors:  A Giacometti; O Cirioni; R Ghiselli; L Goffi; C Viticchi; F Mocchegiani; A Riva; F Orlando; V Saba; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

7.  Differentiation of clonal complex 59 community-associated methicillin-resistant Staphylococcus aureus in Western Australia.

Authors:  Geoffrey W Coombs; Stefan Monecke; Ralf Ehricht; Peter Slickers; Julie C Pearson; Hui-Leen Tan; Keryn J Christiansen; Frances G O'Brien
Journal:  Antimicrob Agents Chemother       Date:  2010-03-08       Impact factor: 5.191

Review 8.  Current and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns.

Authors:  Deborah A Williamson; Glen P Carter; Benjamin P Howden
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

9.  Mupirocin/chlorexidine to prevent methicillin-resistant Staphylococcus aureus infections: post hoc analysis of a placebo-controlled, randomized trial using mupirocin/chlorhexidine and polymyxin/tobramycin for the prevention of acquired infections in intubated patients.

Authors:  C Camus; V Sebille; A Legras; B Garo; A Renault; P Le Corre; P-Y Donnio; A Gacouin; D Perrotin; Y Le Tulzo; E Bellissant
Journal:  Infection       Date:  2014-01-25       Impact factor: 3.553

10.  Community-acquired pneumonia due to pandemic A(H1N1)2009 influenzavirus and methicillin resistant Staphylococcus aureus co-infection.

Authors:  Ronan J Murray; James O Robinson; Jodi N White; Frank Hughes; Geoffrey W Coombs; Julie C Pearson; Hui-Leen Tan; Glenys Chidlow; Simon Williams; Keryn J Christiansen; David W Smith
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.